Gilead Sciences, Inc. $GILD Shares Acquired by Cornerstone Wealth Group LLC

Cornerstone Wealth Group LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 20.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,822 shares of the biopharmaceutical company’s stock after acquiring an additional 472 shares during the period. Cornerstone Wealth Group LLC’s holdings in Gilead Sciences were worth $313,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of GILD. Brighton Jones LLC boosted its position in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 2,450 shares during the last quarter. Bison Wealth LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter worth approximately $215,000. GAMMA Investing LLC boosted its position in shares of Gilead Sciences by 24.9% in the first quarter. GAMMA Investing LLC now owns 22,760 shares of the biopharmaceutical company’s stock worth $2,550,000 after acquiring an additional 4,532 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Gilead Sciences by 4.7% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 292,966 shares of the biopharmaceutical company’s stock valued at $32,827,000 after buying an additional 13,194 shares in the last quarter. Finally, Hanson & Doremus Investment Management lifted its position in Gilead Sciences by 1,024.6% during the first quarter. Hanson & Doremus Investment Management now owns 2,744 shares of the biopharmaceutical company’s stock valued at $307,000 after buying an additional 2,500 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Trading Up 0.2%

GILD opened at $118.48 on Wednesday. The firm has a market capitalization of $147.01 billion, a P/E ratio of 23.60, a P/E/G ratio of 0.80 and a beta of 0.34. The firm’s 50 day moving average is $114.84 and its 200-day moving average is $110.35. Gilead Sciences, Inc. has a 52-week low of $84.80 and a 52-week high of $121.83. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business’s revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s payout ratio is 62.95%.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the sale, the insider owned 113,193 shares in the company, valued at approximately $12,855,329.01. The trade was a 2.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the sale, the chief financial officer owned 159,555 shares of the company’s stock, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 66,000 shares of company stock worth $7,632,100. Insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on GILD. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Cantor Fitzgerald lifted their price target on shares of Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a research report on Tuesday, August 19th. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.08.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.